摘要
目的分析布地奈德联合孟鲁司特对咳嗽变异性哮喘患者血清炎性因子、免疫功能及肺功能的影响。方法选择2014年5月至2017年3月在我院进行治疗的80例咳嗽变异性哮喘患者为研究对象,随机分为观察组与对照组,每组40例。观察组患者应用布地奈德联合孟鲁司特治疗,对照组采用单独布地奈德治疗,观察两组患者治疗效果、日间和夜间咳嗽症状评分、血清炎症因子、免疫功能以及肺功能指标的变化情况。结果观察组患者总有效率(95.50%)比对照组(77.50%)更高,两组比较差异有统计学意义(P<0.05);经治疗后,两组患者的日间和夜间咳嗽症状评分均有所下降,观察组(0.99±0.31)分、(1.72±0.39)分低于对照组(1.63±0.38)分、(1.06±0.34)分,两组比较差异有统计学意义(P<0.05);经治疗后,两组患者Ig E、IL-4、TNF-α水平均有所下降,观察组[(689.24±163.21)U/ml、(54.96±8.72)ng/L、(534.67±105.36)ng/L]低于对照组[(1 268.17±197.53)U/ml、(92.64±11.35)ng/L、(870.56±151.64)ng/L](P<0.05);经治疗后,两组患者CD4^+、CD4^+/CD8^+水平升高,观察组(41.59%±4.62%、1.78±0.25)高于对照组[(37.01%±4.55%)、(1.39±0.27)],CD8^+水平下降,观察组(23.27%±2.68%)低于对照组(27.15%±2.24%)(P<0.05);经治疗后,两组患者FVC、FEV_1、PEF均有升高,观察组[(3.86±0.44)L、(2.78±0.25)L、(3.74±0.91)L/s]高于对照组[(3.19±0.47)L、(2.31±0.21)L、(2.89±0.85)L/s](P<0.05)。结论布地奈德联合孟鲁司特对咳嗽变异性哮喘患者疗效显著,可缓解患者的咳嗽症状,降低炎症因子,改善免疫功能和肺功能指标,推荐应用于临床。
Objective To investigate the effect of budesonide combined with montelukast on serum inflammatory factors,immune function and pulmonary function in patients with cough variant asthma. Methods Totally 80 patients with cough variant asthma who were treated in our hospital from May 2014 to March 2017 were randomly divided into observation group and control group,40 patients in each group. Patients in observation group were treated with budesonide combined with montelukast,while control group was only treated with budesonide. The effects of treatment,daytime and nighttime cough symptom scores,serum inflammatory factors,immune function and pulmonary function were observed. Results The total effective rate（95. 50%） in observation group was higher than that in control group（77. 50%）（P〈 0. 05）; after treatment,concerning the day and night cough symptoms,the observation group [（0. 99± 0. 31） min and（1. 72 ± 0. 39） min] was better than control group [（1. 63 ± 0. 38） min and（1. 06 ± 0. 34） min]（P〈 0. 05）. After treatment,the levels of IgE,IL-4 and TNF-α were decreased in both groups,and those in observation group [（68. 9. 2 ± 163. 21） U/ml,（54. 96 ± 8. 72） ng/L,（534. 67 ± 105. 36） ng/L]was lower those in control group[（1 268. 17 ± 197. 53） U/ml,（92. 64 ± 11. 35） ng/L,（870. 56 ± 151. 64） ng/L]（P〈 0. 05）. After treatment,CD4~＋and CD4~＋/CD8~＋levels were elevated in both groups,and the levels in observation group（41. 59% ± 4. 62%,1. 78 ±0. 25） were lower than those of control group（37. 01% ± 4. 55%,1. 39 ± 0. 27）; CD8~＋level decreased,which was lower in observation group [（23. 27% ± 2. 68%） vs.（27. 15% ± 2. 24%）,P〈 0. 05]. After treatment,the levels of FVC,FEV_1 and PEF in both groups were increased,and those in observation group [（3. 86 ± 0. 27） L,（2. 78 ± 0. 25）L,（3. 74 ± 0. 91） L/s] were higher than those of control group [（3. 19 ± 0. 47） L,（2. 31 ± 0. 21） L,（2. 89 ± 0. 85）L/s]（P〈 0.
作者
程联云
CHENG Lian-yun(Department of Respiratory,Shanghai Punan Hospital of Pudong New District,Shanghai 200125,China)
出处
《实用药物与临床》
CAS
2018年第7期807-810,共4页
Practical Pharmacy and Clinical Remedies
